▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Brian Feroldi

TMFTypeoh

Brian Feroldi has been covering the healthcare and technology industries for The Motley Fool since 2015. Brian's investing strategy is to buy high-quality companies and then let compounding work its magic. See all of his articles here.

Recent Articles by Brian Feroldi

Aug 5, 2015 by Brian Feroldi

Why ACADIA Pharmaceuticals Inc Jumped 17% in July

Are investors right to bid up the stock ahead of its first NDA submission?

Aug 5, 2015 by Brian Feroldi

Why Shares of Theravance Inc Sank 12% in July

The royalty management company's stock dropped during the month after reporting mixed results for the second quarter.

Aug 5, 2015 by Brian Feroldi

Why Orexigen Therapeutics Inc Stock Fell 18% in July

Tension between Orexigen and its marketing partner Takeda Pharmaceuticals continues to build after reports of a recall on obesity medication Contrave surface.

Aug 4, 2015 by Brian Feroldi

Why Keryx Biopharmaceuticals Stock Plunged 18% in July

Keryx shareholders received some good news from European regulators, but the share price fell anyway on an analyst downgrade. Is this a buying opportunity, or should you keep away?

Aug 4, 2015 by Brian Feroldi

5 Reasons to Buy Keryx Pharmaceuticals

Small cap biotech Keryx Pharmaceuticals' newly launched drug Auryxia looks like a clinical winner, yet the stock has been hit hard recently. Here are 5 reasons why Keryx could be a buy today.

Aug 1, 2015 by Brian Feroldi

The Blockbuster Potential of Biogen Inc's Pipeline

Blue chip biotech stock Biogen has a strong pipeline full of drugs that could offer multi billion dollar opportunity. Lets take a closer look at the potential.

Jul 31, 2015 by Brian Feroldi

Why Shares of Molina Healthcare Inc Jumped Today

Medicaid focused health insurer Molina Healthcare popped today after reporting second quarter earnings. Were investors right to bid up the stock based on the news?

Jul 30, 2015 by Brian Feroldi

Why Genocea Biosciences Inc Stock Dropped Today

Shares of Genocea Biosciences fell today after the company announced the pricing terms of their secondary offering. Is the move meaningful, or just market noise?

Jul 30, 2015 by Brian Feroldi

Why Cempra Inc Shares Fell Today

Shares of Cempra fell today after reporting second quarter earnings. Is the move warranted, or just market noise?

Jul 30, 2015 by Brian Feroldi, Selena Maranjian, and Dan Caplinger

3 Stocks that Are Fool's Gold

These stocks hold big potential to make you a millionaire, but they are also extremely high risk. Our group of experts think you should stay away from these 3 stocks.

Jul 30, 2015 by Brian Feroldi

Attention New Biotech Investors: Biogen Inc's Recent Weakness Is Your Opportunity

Biogen's stock has fallen hard recently based on slower than expected earnings growth of Tecfidera. Still, the company boasts a number of billion dollar drugs and a strong pipeline that make it an ideal choice for new biotech investors.

Jul 29, 2015 by Brian Feroldi

This Winning Biotech Stock Looks Like a Buy

Jazz Pharmaceuticals is up more than 20-fold over the past five years, and strong growth in the company's narcolepsy drug Xyrem makes this Foolish contributor believe the good times will continue to roll.

Jul 29, 2015 by Brian Feroldi

The Secret to Vertex Pharmaceuticals' Success

Originally set out to treat the hepatitis C market, Vertex has successfully pivoted its focus to the cystic fibrosis market instead, where it looks poised for strong growth.

Jul 28, 2015 by Brian Feroldi

Why ICON PLC Stock Soared Today

Shares of the contract research organization soared more than 16% today. Is the move meaningful, or just market noise?

Photo by Images_of_Money : Flickr Creative Commons

Jul 28, 2015 by Brian Feroldi

3 Big Biotech Buybacks That Investors Should Love

Big biotech companies are flush with cash and are using it to reward shareholders. Here are three companies that are spending big on share buybacks.

Photo by 401(k) 2012 flickr creative commons

Jul 27, 2015 by Brian Feroldi, Selena Maranjian, and Todd Campbell

3 Stocks for Retirees to Buy

Retirees should be looking for rock-solid businesses that offer good long-term growth prospects and shareholder friendly management teams. Here are 3 company's that fit the bill today.

Jul 27, 2015 by Brian Feroldi

Regeneron Pharmaceuticals and Sanofi Grab a Blockbuster FDA Approval

The FDA has given the nod to the sale of Praluent, the first of a new class of cholesterol lowering medications, and a blockbuster opportunity for the company's.

Jul 24, 2015 by Brian Feroldi

Why Shares of Keryx Biopharmaceuticals Fell Today

Share of Keryx Biopharmaceuticals fell hard today on heavy volume, despite issuing a press release with good news. What was behind the stocks negative movement?

Jul 24, 2015 by Brian Feroldi

Why Shares of Cepheid Dropped Today

Molecular diagnostic test company Cepheid stock dropped 12% today after reporting earnings last night. Is the move justified, or just market noise?

Jul 24, 2015 by Brian Feroldi

Why Shares of IGI Laboratories, Inc. Soared Today

IGI Laboratories stock surged more than 19% today after reporting second quarter results. Where results really good enough to justify such a strong move?

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services